Skip to main content

Drug Interactions between Brukinsa and olutasidenib

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

zanubrutinib olutasidenib

Applies to: Brukinsa (zanubrutinib) and olutasidenib

Consumer information for this interaction is not currently available.

MONITOR: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of zanubrutinib, which is primarily metabolized by the isoenzyme. When zanubrutinib was administered in clinical study subjects with multiple doses of rifampin, a potent CYP450 3A4 inducer, zanubrutinib peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by 92% and 93%, respectively. When coadministered with multiple doses of rifabutin, a moderate CYP450 3A4 inducer, zanubrutinib Cmax and AUC decreased by 48% and 44%, respectively, in healthy subjects. Based on pharmacokinetic modeling, coadministration with multiple doses of efavirenz, another moderate CYP450 3A4 inducer, is predicted to decrease zanubrutinib Cmax and AUC by 58% and 60%, respectively. Reduced efficacy of zanubrutinib may occur. The interaction has not been studied with other, less potent inducers.

MANAGEMENT: The potential for diminished pharmacologic effects of zanubrutinib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.

Drug and food interactions

Major

zanubrutinib food

Applies to: Brukinsa (zanubrutinib)

Grapefruit juice and Seville orange juice can increase the blood levels of zanubrutinib. This may increase side effects such as rash, diarrhea, constipation, cough, hemorrhage, development of other cancers, abnormal heart rhythm, and impaired bone marrow function resulting in low numbers of different types of blood cells. You may also be more likely to develop anemia, bleeding problems, or infections due to low blood cell counts. You should avoid the consumption of Seville oranges, Seville orange juice, grapefruit and grapefruit juice during treatment with zanubrutinib. Be sure to take the medication at approximately the same time(s) everyday to maintain consistent blood levels and effects. Talk to your doctor or pharmacist if you have questions on how to take this or other medications you are prescribed. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Moderate

olutasidenib food

Applies to: olutasidenib

Olutasidenib should be taken at about the same time each day, on an empty stomach at least 1 hour before or 2 hours after a meal. Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.